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Background: Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients 
aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month 
efficacy and safety of PRM in insomnia patients aged 18–80 and lack of withdrawal and rebound 
symptoms upon discontinuation.
Objective: To investigate the efficacy, safety, and withdrawal phenomena associated with 
6–12 months PRM treatment.
Methods: Data from a prospective 6–12-month open-label study of 244 community dwelling 
adults with primary insomnia, who had participated in a placebo-controlled, double-blind dose-
ranging trial of PRM. Patients received PRM nightly, followed by a 2-week withdrawal period. 
Main outcome measures were patient-reported sleep quality ratings (diary), adverse events, 
vital signs, and laboratory tests recorded at each visit, and withdrawal symptoms (CHESS-84 
[Check-list Evaluation of Somatic Symptoms]). Nocturnal urinary 6-sulfatoxymelatonin 
excretion, a measure of the endogenous melatonin production, was assessed upon discontinuing 
long-term PRM.
Results: Of the 244 patients, 36 dropped out, 112 completed 6 months of treatment, and the 
other 96 completed 12 months of treatment. The mean number of nights by which patients 
reported sleep quality as “good” or “very good” was significantly higher during PRM than 
before treatment. There was no evidence of tolerance to PRM. Discontinuation of PRM was 
not associated with rebound insomnia or withdrawal symptoms; on the contrary, residual 
benefit was observed. PRM was well tolerated, and there was no suppression of endogenous 
melatonin production.
Conclusion: Results support the efficacy and safety of PRM in primary insomnia patients 
aged 20–80 throughout 6–12 months of continuous therapy. PRM discontinuation even after 
12 months was not associated with adverse events, withdrawal symptoms, or suppression of 
endogenous melatonin production.
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Introduction
Insomnia is a common complaint characterized by difficulties to initiate or maintain sleep 
and/or poor quality of sleep. These complaints last at least 1 month and have negative 
effects on subsequent daytime functioning.1–3 Patients may suffer immensely from poor 
quality of sleep, even when their sleep quantity is within the normal limits.1,2 Poor sleep 
quality adversely affects physical and mental health, wellbeing, activities of daily liv-
ing, driving skills, memory, productivity, and satisfaction with life.4–11 The prevalence 
of complaints on poor sleep quality increases with age.6,7,12 Insomnia is often chronic Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(lasting more than 3 months),13 and although benzodiazepines 
and Z drugs (zolpidem, zopiclone, zaleplon, and derivates) are 
considered inadequate for management of chronic insomnia 
patients, patients tend to use these drugs over extended periods 
of time varying from 4 weeks to several years.14
Melatonin (N-acetyl-5-methoxytryptamine) is   produced at 
night by the pineal gland and signals darkness to the   organism 
to facilitate synchronization of the circadian clock with 
the ambient day–night cycle.15 In addition, melatonin is an 
endogenous sleep promoter acting at brain networks involved 
in sleep regulation.16 A   prolonged-release melatonin (PRM) 
2 mg formulation (Circadin®, Neurim Pharmaceuticals, 
  Tel-Aviv, Israel) is licensed in Europe and other countries for 
the treatment of primary insomnia in patients aged 55 years 
and over for a duration of up to 3 months. The approval 
was based on a series of double-blind placebo-controlled 
clinical trials of PRM (3 weeks) treatment in patients aged 
55 years and older. The rationale for this age limit was 
based on the well documented age-associated decline in the 
capacity to produce the   endogenous hormone,17–19 the decline 
in biological clock output, and the age-related increase 
in the incidence of poor sleep quality.10,20 PRM circumvents 
the fast clearance of the   hormone and essentially mimics 
the physiological patterns of the endogenous secretion of 
melatonin.
In a recent double-blind, placebo-controlled trial, the 
long-term (6 months) efficacy and safety of PRM was dem-
onstrated in patients with insomnia aged 18–80; patients aged 
55 years and older were found to be those who benefit most 
from the drug.21,22 It was also found that efficacy was main-
tained and even enhanced during the 6 months of treatment 
with PRM, without evidence of tolerance. Discontinuation of 
PRM after either 3 weeks or 6 months was not associated with 
rebound insomnia or withdrawal symptoms.21–25 The present 
study aimed to demonstrate: (1) that the efficacy and safety 
of PRM (2 mg) in adults with insomnia who are permanently 
taking the medication is maintained for up to 12 months; 
(2) that there are no withdrawal symptoms associated with 
discontinuation of the treatment, even after 12 months; and 
(3) that normal endogenous melatonin levels are produced 
despite long-term administration (6 months) of PRM 2 mg.
Methods
Patients
Participants were community dwelling men and women 
aged 20–80 years, diagnosed as having primary insomnia 
according to the Diagnostic and Statistical Manual of Mental 
Disorders (revision IV) criteria. Exclusion criteria were 
respiratory related sleep disorders, circadian rhythm sleep 
disorders, dyssomnias not otherwise specified, sleep disorder 
secondary to medical conditions, significant psychiatric 
or neurological disorders (anxiety, depression, dementia, 
psychosis), or the use of hypnotic medications in the past 
2 weeks.
study design
The study was carried out in 30 general practitioners’ clinics 
in France and Israel. The study was conducted in accordance 
with the International Conference on Harmonisation (ICH) 
Guidelines and the provisions of the Declaration of Helsinki 
(18th World Medical Assembly 1964) and revisions (48th 
World Medical Assembly – South Africa 1996). In addition, 
this study was undertaken in accordance with current ICH 
Guidelines on Good Clinical Practice on the conducting and 
monitoring of clinical studies. The protocol and the statement 
of informed consent were approved by independent ethics 
committees (in France, Comité Consultatif de Protection des 
Personnes dans la Recherche Biomédicale; and in Israel, the 
Central EC of the Wolfson Medical Center, Holon) prior to 
each center’s study initiation. All patients provided written 
informed consent prior to enrolment.
All participants had a 1 week run-in period with placebo 
(baseline) followed by a 6-week placebo-controlled dose-
ranging study with PRM. Completers who gave their consent 
for the long-term study were allowed to enter the prospective 
6–12-month open-label study. In this phase, all patients 
received (open-label) PRM 2 mg (Circadin®). Participants 
were instructed to take the study medication regularly after 
the evening meal, 1–2 hours before bedtime and preferably 
between 21:00–22:00. Treatment compliance was monitored 
in all subjects using a monthly tablet count. Patients with 
significant adverse events were to be withdrawn from the 
study at the discretion of the investigator. All hypnotics or 
treatments used to induce sleep (herbals, antihistamines, 
alcohol) were not allowed during the study. Use of hypnotic 
drugs for up to two times per week at any time during the 
study, were to be recorded as a protocol deviation, and using 
hypnotics three or more times per week led to withdrawal of 
the patient from the study.
Once the first 100 subjects had completed the 26-week 
(6 months) open-label period, they were not given the option 
to continue up to 52 weeks, as safety data for 26 weeks 
was requested by regulatory authorities. They therefore 
underwent the 2-week withdrawal period, their study was 
terminated, and their safety data were summarized. The 
remaining patients continued PRM treatment up to 52 weeks Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(12 months), with a 2-week follow-up period without study 
medication (withdrawal).
During the week before each follow-up visit (weeks 1, 
7, 13, 23, 33, and 59 and withdrawal phase weeks 35/61), 
all participants were asked to complete a daily sleep diary 
  comprising two questions: “How was your night?”, regarding 
their sleep quality in the previous night (QOS), and “How was 
your mood during the day?”, assessing their perceived mood 
during the previous day (QOD). QOS and QOD were rated on 
a five-grade severity scale (very bad, bad, fair, good, and very 
good). The diary was completed also during the 2-week with-
drawal periods (week 35 for those who completed 26 weeks 
of PRM treatment, and week 61 for those who completed 52 
weeks of PRM treatment). Physical examination, vital signs 
assessment, and evaluation of safety parameters, including 
adverse events and unusual events in the patient diary, were 
performed at each visit. Safety laboratory tests were performed 
on each visit. At the end of the withdrawal period, the patients 
were assessed by the mini mental state examination and 
CHESS-84 (Check-list Evaluation of Somatic Symptoms).26 
This scale evaluates a list of somatic symptoms on digestive 
system, cardiovascular system, central nervous system, and 
specifically sleep and daytime parameters.
endogenous melatonin production
It is widely accepted27 that the levels of the major melatonin 
metabolite 6-sulphatoxymelatonin (6SMT) in urine is a 
reliable measure of endogenous melatonin production. The 
levels of 6SMT in urine were determined in a group of 15 
of the insomnia patients (mean ± standard deviation [SD]: 
64 ± 6 years) who had been treated for 6 months with PRM. 
6SMT was assessed 2 weeks after withdrawal of the drug. 
Patients were asked to collect all urine excreted between 20:00 
and 8:00 hours (for nocturnal production) and between 8:00 
and 20:00 hours (for daytime production) in separate contain-
ers provided by the investigator. To enhance compliance, no 
specific instructions were given regarding lighting conditions 
while sleeping. Urine was delivered to the local center or 
laboratory, the volume was measured and recorded, and a 
1 mL sample from each collection was retained and frozen 
until measurement of urinary 6SMT. Determination of 6SMT 
was performed in duplicates as described in Arendt et al27 
using the anti 6SMT antibody and 6SMT calibration standards 
provided by Stockgrand (Surrey, UK).
statistical analyses
The number of nights per week rated “good” and “very 
good” in the sleep diary was calculated for the 1-week run-in 
period and for weeks 7, 13, 23, 33, and 59, and during the 
2 weeks following withdrawal. The mean rate of “good” 
and “very good” nights per week was summarized using 
descriptive statistics. Two-sided t-tests were used to test the 
null hypothesis that the rates after treatment were equal to 
those at baseline. P-values were reported.
Descriptive statistics were also used for assessing 
adverse events, changes in laboratory parameters, changes 
in physical examination parameters, and vital signs. For 
withdrawal symptoms, the number of patients reporting 
somatic symptoms possibly, probably, or definitely related to 
treatment discontinuation during the withdrawal period was 
summarized using CHESS-84. Two-sided Fisher’s exact tests 
were used to compare adverse event incidence in the ,55 
and $55 years age groups.
Results
study population
A total of 244 patients entered the prospective 6–12-month 
open-label study (safety population). Of those, 36 dropped 
out, 112 completed 26 weeks, and the other 96 completed 
52 weeks of the open-label PRM treatment. Altogether, 
208 patients were included in the full analysis set (FAS) 
  population. Three patients who completed the 26 week 
treatment phase and did not undergo a withdrawal period 
were included in the FAS analyses, and their withdrawal 
data were missing (Figure 1). The main reasons for   dropping 
out were withdrawal of consent (N = 16), termination of 
study by sponsor (N = 10), and protocol violation (N = 7). 
Mean ± SD age of the safety population was 55.3 ± 13.0 years 
(132 aged $ 55 years and 112 aged 20–54 years), and 69% 
were females. With the exception of one participant of Asian 
origin, all subjects were Caucasians. A total of 79% were 
taking concomitant medications at entry, and 94% took at 
least one dose of a concomitant medication during the study. 
The concomitant medications used in more than 5% of the 
244 patients were paracetamol (acetaminophen) in 35/208 
(14%), statins in 25 (10%), acetylsalicylic acid in 22 (9%), 
amoxycycline and ibuprofen in 17 (7%) each, levothyroxine 
sodium in 17 and thyroxine in 7 patients (altogether 10%), 
famotidine, glibenclamide, omeprazole, metformin, estradiol, 
ergynon in 12 (5%) patients each.
sleep quality during the long-term period
The mean (+standard error of the mean [SEM]) percentage 
of nights per week reported as “good sleep” or “very good 
sleep” as calculated from the night-time sleep diary in the 
last 7 nights before each visit is presented in Figure 2A Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(FAS population). The mean (+SEM) percentage of nights 
per week scored by the patients as “good” or “very good” 
increased progressively with treatment duration, reaching 
plateau levels between weeks 13 and 23. At the plateau 
level, 54%–56% of nights per week were scored as “good” 
or “very good” (ie, 3.8 nights per week) compared with 26% 
(ie, 1.8 nights per week) at baseline (P , 0.001, t-test), and 
this was maintained throughout the entire PRM treatment 
period. Following discontinuation of treatment and 2 weeks 
withdrawal, the percentage declined to around 44% (ie, 3.1 
nights per week scored as “good” or “very good” on   average), 
regardless of whether patients had been treated for 26 or 
52 weeks (Figure 2). Although the percentage of nights per 
week scored as “good” or “very good” at withdrawal was 
lower than during the PRM treatment, it was still significantly 
better than at baseline before PRM treatment (P , 0.001 for 
both 26 and 52 weeks).
At baseline, 57% of days (4.2 days per week) were 
scored as “good” or “very good” mood by the patients. 
This score increased progressively with PRM treatment, 
Screened (N = 288)
Included in the dose ranging study (N = 263) Excluded (N = 25)
Discontinued (N = 19)
Completed withdrawal phase
following 6 months treatment
(N = 109)
Did not complete the withdrawal
phase following 6 months 
treatment (N = 3)
Dropped-out (N = 36)
Non-eligibility
Withdrawal of consent (N = 2)
Other (N = 1)
Entered the long-term study (N = 244)
Completed 6 months (N = 208)
Completed 12 months (N = 96)
Completed withdrawal phase following 12 months treatment (N = 96)
Adverse event (N = 5)
Protocol violation (N = 2)
Withdrawal of consent (N = 8)
Lack of efficacy (N = 4)
Lack of efficacy (N = 4)
Lost to follow-up  (N = 1)
Withdrawal of consent (N = 14)
Protocol violation (N = 7)
Termination of study by sponsor (N = 10)
Figure 1 Overall study patient disposition (Consolidated standards for Reporting Trials diagram). The study comprised 1-week, single-blind placebo run-in followed by 
6-week dose-ranging study with 3 doses of PRM or placebo. Completers were allowed to continue PRM treatment for 26 weeks (n = 100) or 52 weeks (all the rest) followed 
by 2 weeks run-out on placebo. 
Abbreviation: PRM, prolonged-release melatonin.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reaching   plateau levels of 67%–68% (4.7 days per week) 
between weeks 13 and 23 (P , 0.002). This plateau level was 
maintained until the end of the treatment phase. However, 
following PRM discontinuation and the 2-week withdrawal 
period, the percentage of days scored as “good” or “very 
good” decreased to approximately baseline values.
Because PRM is licensed to patients aged 55 years and 
older, the long-term efficacy in patients younger and older 
than 55 years was compared. For patients younger than 
55 years, the percentage of nights per week scored by the 
patients as “good” or “very good” increased progressively 
with treatment duration from 30% at baseline, reaching 
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Figure 2 Mean + standard error of the mean values for: (A) percentage of nights per week rated “good” or “very good” from the sleep diary during the baseline week and 
the last week preceding each visit during the treatment phase and withdrawal phase; and (B) percentage of days per week with mood rated “good” or “very good” from the 
sleep diary during the baseline week and the last week preceding each visit during the treatment phase and withdrawal phase. Blank circles indicate the values recorded at 
the withdrawal period following respective 26 or 52 weeks treatment with prolonged-release melatonin. The x-axis depicts the time since entering the dose ranging phase 
of the study. Week 1 is baseline, week 8 is the first week of the long-term period that lasted 26 weeks (ending on week 31) and 52 weeks (ending on week 59) followed by 
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  plateau levels of 58%–57% between weeks 13 and 23 
  respectively (P , 0.001), which was maintained for the 
rest of the treatment period. The percentage of days scored 
by patients as “good” or “very good” mood also increased, 
from 62% at baseline, reaching plateau levels of 68%–70% 
between weeks 13 and 23 respectively. Following PRM 
  discontinuation and the 2-week withdrawal period, the 
  percentage of nights scored as “good” or “very good” 
decreased to 50%, and the percentage of days scored as 
“good” or “very good” decreased to 68%; both were higher 
than baseline values.
Similarly, for patients who were 55 years and over, 
the percentage of nights per week scored by the patients 
as “good” or “very good” increased progressively with 
treatment duration from 23% at baseline, reaching plateau 
levels of 52%–50% between weeks 13 and 23 respectively 
(P , 0.001). The percentage of days scored by patients as 
“good” or “very good” mood also increased, from 52% 
at baseline, reaching plateau levels of 67%–66% between 
weeks 13 and 23 respectively (P , 0.001). Following PRM 
discontinuation and the 2-week withdrawal period, the per-
centage of nights scored as “good” or “very good” decreased 
to 38%, and the percentage of days scored as “good” or “very 
good” decreased to 57%, which were also still higher than 
baseline values.
serious adverse events
No deaths were reported during any phase of the study. 
Nine adverse events were considered “serious”: one (pelvic 
fracture) was reported during run-in under placebo, and eight 
events during the 26–52 weeks open-label phase of the study. 
These included (one case each) duodenal sphincterectomy, 
dilatation of bile duct, elective surgery for worsening of 
venous insufficiency, fall with wrist fracture, fall from a 
ladder with loss of consciousness, acute subendocardial 
anteriolateral myocardial infarction, tibial fracture, syncope 
due to aortic stenosis, and cholecystitis due to gallstones. 
All of these events were considered to be “not related” to the 
study medication. No patients withdrew as a result of adverse 
events during the open-label phase of the study.
safety parameters
Out of the 244 patients in the safety population, 48 patients 
(18%) reported a total of 63 adverse events during the run-in 
period on placebo. The total number of weeks on PRM 
therapy for the 244 patients was 8475.5. The mean ± SD 
  treatment duration with PRM was 243.5 ± 109.90 days. 
Out of the 244 subjects patients in the safety population, 
153 (63%) reported adverse events that emerged during the 
26–52 weeks treatment phase of the study; the most com-
monly reported events were pharyngitis (12.4%), back pain 
(11.8%), asthenia (9.1%), upper respiratory tract infection 
(8.5%), bronchitis (7.8%), arthralgia and sinusitis (7.2% 
each), headache and rhinitis (5.9% each), and gastroenteri-
tis (5.2%). In 7% of the patients, the adverse events were 
considered by the investigator to be definitely, probably, or 
possibly related to study medication. Of these, the most com-
monly reported adverse events were dizziness in four patients 
(1.6%) and headache in three patients (1.2%). No noticeable 
changes were found in hematologic and biochemical labora-
tory tests at any time-point during the study. Furthermore, 
there were no differences in the number and nature of changes 
from baseline in the physical examination between patients 
treated for the first 6 months and those treated for a whole 
year of single blind treatment (Table 1). In order to evaluate 
whether safety problems occur more with prolonged use, we 
Table 1 number of patients demonstrating a change from normal to abnormal physical examination observations between baseline 
and study week 33 or 59 (safety population)
Body system Number of patients with changes (treatment) Difference in  
incidence rates  
between baseline  
to weeks 59 and 33
Baseline to  
week 33  
N = 112
Baseline to  
week 59  
N = 99
eyes, ears, nose and throat 8 (6.7%) 9 (9.1%) 2.4%
Cardiovascular 2 (1.8%) 0 -2%
Respiratory 3 (2.7%) 3 (3.0%) 0.3%
Abdomen 3 (2.7%) 3 (3.0%) 0.3%
Urogenital 0 3 (3.0%) 3%
neurological 0 3 (3.0%) 3%
Musculoskeletal 6 (5.4%) 6 (6%) 0.6%
Lymph nodes 0 0 0
Total shifts 25 (22.3%) 38 (38.4%) 16%Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 summary of age group comparisons on adverse event incidence
Body system All  
(N = 244)
$55 years  
(N = 133)
,55 years  
(N = 111)
P-valueb
Adverse event
No Ratea No Ratea No Ratea
Application site disorders 3 0.04 2 0.04 1 0.03 1.000
Body as a whole – general disorders 43 0.51 24 0.54 19 0.48 0.867
Central and peripheral nervous system disorder 30 0.35 18 0.40 12 0.30 0.561
gastrointestinal system disorders 35 0.41 20 0.45 15 0.38 0.855
Metabolic and nutritional disorders 11 0.13 5 0.11 6 0.15 0.555
Musculoskeletal system disorders 46 0.54 27 0.60 18 0.45 0.413
Psychiatric disorders 17 0.20 7 0.16 10 0.25 0.316
Reproductive disorders, female 7 0.08 2 0.04 5 0.13 0.251
Resistance mechanism disorders 22 0.26 8 0.18 14 0.35 0.115
Respiratory system disorders 64 0.76 36 0.80 28 0.71 0.771
secondary terms 6 0.07 5 0.11 1 0.03 0.224
skin and appendages disorders 13 0.15 6 0.13 7 0.18 0.579
Urinary system disorders 17 0.20 11 0.25 6 0.15 0.454
Vascular (extracardiac) disorders 3 0.04 1 0.02 2 0.05 0.594
Vision disorders 3 0.04 1 0.02 2 0.05 0.594
Total 153 1.81 83 1.85 69 1.74 1.000
Notes: aRate of patients with adverse event per 100 patient-weeks of therapy; bTwo-sided Fisher’s exact test.
have calculated the differences in the rate of changes from 
normal to abnormal status, between baseline to either week 
33 or week 59. As can be seen in Table 1, the incidence of 
such changes was lower in the period between 33 and 59 
than between baseline and week 33.
Because PRM is licensed to patients aged 55 years and 
older, the long-term safety profiles in patients younger and 
older than 55 years were compared. The total rate of patients 
with adverse events per 100 patient-weeks of PRM therapy, 
and in the two age groups is presented in Table 2.
Patients younger than 55 years (N = 111) had 3968 weeks 
and those older than 55 (N = 132) had 4480 weeks of PRM 
exposure. There were no differences in rate and nature of 
adverse events between patients above and below 55 years 
of age (Table 2).
Withdrawal effects
Withdrawal effects after long-term administration (26 and 
52 weeks) were assessed by comparing adverse event rates 
during the 2-week withdrawal phase and the long-term 
open-label phase using the CHESS-84 questionnaire. Out 
of 100 subjects who underwent a 2-week withdrawal fol-
lowing 26 weeks of treatment with PRM, 20% reported 
adverse events during the withdrawal phase. The most 
commonly reported adverse event during this period was 
sinusitis, reported by three patients. Among the 96 subjects 
who underwent a 2-week withdrawal following 52 weeks 
treatment with PRM, 13% reported adverse events during 
the withdrawal phase. The most commonly reported events 
were insomnia and urinary tract infections, each reported 
by two patients. No consistent changes in any laboratory 
finding were noted.
The number of somatic symptoms reported in CHESS-84 
during withdrawal following 26 and 52 weeks of PRM treat-
ment are summarized in Table 3. Overall, 24 patients (24%) 
of those treated for 33 weeks and 21 (22%) of those treated 
for 52 weeks reported somatic symptoms possibly, probably, 
or definitely related to study treatment. Most of those were 
relate to sleep.
Rebound insomnia is defined as a worsening of the 
insomnia parameters below pre-treatment values. Based on 
the CHESS-84 questionnaire, during the withdrawal period, 
11% of patients reported difficulty in falling asleep, and in 
25% of those they reported the difficulty to be moderate, 
severe, or extreme. At baseline, 53% of the patients reported a 
score for sleep latency of $3 (more than 30 minutes to more 
than 2 hours) in their sleep diary. Therefore, the number of 
patients having difficulties in falling asleep during withdrawal 
is apparently much lower than those having had difficulties 
in falling asleep at baseline.
Also, based on the CHESS-84 questionnaire, during the 
withdrawal period, 11% of the patients reported waking dur-
ing the night at withdrawal and in 29% of those, the reported 
difficulty was defined as moderate, severe, or extreme. At 
baseline, 24% of the patients reported on waking up more 
than three times a night. Therefore, the number of patients 
waking during the night at withdrawal did not appear to differ 
greatly from that reported in the patients’ diaries at baseline. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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In addition, there was no evidence of new somatic symptoms 
not related to sleep, experienced during withdrawal that had 
not been previously experienced at baseline. Altogether, 
the CHESS-84 score for discontinuation of PRM after 33 or 
52 weeks was 1.37.
The score of all subjects who completed the Mini-Mental 
State Examination were within the normal range in subjects 
of all age groups. There was no apparent decline in the cogni-
tive status following PRM treatment for 33 or 52 weeks.
endogenous melatonin production
The overnight 6SMT excretion (between 22:00 and 10:00) in 
15 patients who completed 6 months of daily PRM admin-
istration and the following 2 weeks withdrawal of treatment 
was mean ± SD of 15.3 ± 7.7 µg, median 15 µg, range 
4–30 µg. These levels were significantly higher than those 
of a large reference population of patients with insomnia 
of the same age group (mean ± SD of 9.5 ± 7.9 µg, range 
0–47 µg/12-hour night; t-test, P , 0.01) and similar to those 
without insomnia of the same age group (mean ± SD of 
18.1 ± 12.7 µg per 12-hour night) (Figure 3).17,19 Fourteen 
out of the 15 patients were considered to be within the normal 
range of the nocturnal 6SMT (2.9–29.0 µg 6SMT/12-hour 
night).19 A clear diurnal rhythm in melatonin production 
was evident in these patients, with levels of 6SMT over 
daytime hours (10:00–22:00) of mean ± SD 9.80 ± 5.06, 
range 3–19 µg/12-hour day, which is significantly lower than 
the night-time levels (mean ± SD of 15.3 ± 7.7 µg, median 
15 µg, range 4–30 µg; t-test, P , 0.01).
Discussion
Out of 244 patients aged 18–80 years who entered the open-
label phase of the study, 112 patients completed the 6-month 
treatment period, and 96 patients completed the 12-month 
treatment period. This enabled comparison between the effi-
cacy and safety in the second 6 months to the first 6 months of 
treatment, thereby extending our knowledge about long-term 
effects of the drug. A significant improvement in quality of 
night sleep from baseline value was observed with PRM. The 
response evolved gradually, reaching plateau levels between 
weeks 13 and 21 (approximately 54%–56% of nights were 
defined as “good” or “very good” compared with around 26% 
at baseline), and this improvement was maintained through-
out the 12 months of PRM treatment. Because this was an 
open-label phase, it was pertinent to ask whether the apparent 
increase in efficacy during treatment periods of up to 13–21 
weeks is a drug-related clinical benefit or instead linked to 
spontaneous remission of insomnia. A similar enhancement 
in effects of PRM with treatment of up to week 13 was also 
demonstrated in a double-blind placebo-controlled study of 
PRM in insomnia patients.21,22 In agreement with the results of 
other short- and long-term placebo-controlled trials with this 
drug, PRM did not ameliorate and even improved patients’ 
perceived wellbeing during the day.21–25,28 The enhanced 
efficacy over a number of sleep and daytime variables was 
attributed to improvement in the adjustment of the circa-
dian system to the day–night cycle.21,22 It can therefore be 
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Figure 3 Frequency distribution (in percentage of patients) of 6sMT excreted over 
the night by patients completing 26 weeks of PRM treatment followed by 2 weeks of 
withdrawal (big squares; n = 15) compared with that in a historical sample 17,19 of 
untreated insomnia patients of the same age group (small squares; n = 384). 
Abbreviations: 6sMT, 6-sulphatoxymelatonin; PRM, prolonged-release melatonin.
Table  3  somatic  symptoms  during  the  withdrawal  period 
following 26 and 52 weeks of open-label PRM treatmenta
Number (% safety 
population) of patients with 
new symptomsb
26 weeks  
N = 100
52 weeks   
N = 96
Total patients reporting  
somatic symptoms
24 (24%) 21 (22%)
Body system
nonrestorative sleep 13 (13%) 9 (9%)
Waking during the night 11 (11%) 14 (15%)
Difficulty in falling asleep 11 (11%) 10 (10%)
Waking early in the morning 11 (11%) 7 (7%)
Change in dream pattern 6 (6%) 3 (3%)
Drowsiness during the day 5 (5%) 4 (4%)
Dryness of the mouth 4 (4%) 2 (2%)
excessive drowsiness 3 (3%) 4 (4%)
Constipation 2 (2%) 0
stomach aches, cramps 0 2 (2%)
Memory problems increase 0 2 (2%)
Notes:  aEvents  possibly,  probably,  or  definitely  associated  with  treatment;  bAs 
reported in the Chess-84 questionnaire.
Abbreviations: Chess, Check-list evaluation of somatic symptoms; PRM, prolonged-
release melatonin.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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  concluded that there is no tolerance to PRM even upon 
extended use. Rather, some added benefit is seen with pro-
longed treatment duration for 3–4 months, with no signs of 
tolerance even after 12 months.
A good safety profile was observed during treatment with 
PRM 2 mg in the long-term (6- and 12-month) treatment 
period for adult patients, including the elderly with similar 
safety profiles for patients aged 55 years and older and 
younger patients. In addition, no major safety concerns 
followed withdrawal of the study medication. During the 
PRM treatment period, 63% of patients reported adverse 
events; this figure dropped to 20% during the 2-week 
withdrawal period after 26 weeks, and to 13% after 52 weeks 
of PRM treatment. No patients reported serious adverse 
events during the withdrawal period following 26 weeks and 
52 weeks of treatment.
During withdrawal, the amount of days rated as “good” 
and “very good” declined but did not reach baseline levels 
recorded before start of treatment. Daytime mood, which 
was quite high at baseline, also decreased but was still 
higher (not significantly) than baseline levels after 2 weeks 
of withdrawal. Thus, PRM does not cause rebound insom-
nia; on the contrary there are signs of lasting effects of the 
drug after discontinuation. A number of previous studies 
have demonstrated that indeed some effects of PRM do 
not fade away as treatment is discontinued (eg, quality of 
sleep, daytime psychomotor function.24,29 The lasting effect 
of PRM, by which is meant that patients continued to have 
benefit beyond the treatment phase, has not been seen with 
other hypnotic drugs and may represent reinforcement of 
the sleep–wake cycle.
Based on the CHESS-84 questionnaire, during the with-
drawal period, 11% of patients reported difficulty in falling 
asleep and was considered by the investigator to be possibly, 
probably, or definitely related to study medication; in 25% of 
those, the difficulty in falling asleep was rated as moderate, 
severe, or extreme. At baseline, 53% of the study patients 
reported in their sleep diary a score for sleep latency of $3 
(more than 30 minutes to more than 2 hours). Combined 
with the diary-recorded rating of the quality of sleep, which 
indicated that there were no rebound effects, the difficul-
ties of falling asleep during withdrawal probably reflects 
insomnia relapse in these patients.
Also, based on the CHESS-84 questionnaire, during 
the withdrawal period, 11% of patients reported waking, 
which was considered by the investigator to be possibly, 
probably or definitely related to study medication; in 29% of 
those, the difficulty in waking during the night was rated as 
moderate, severe, or extreme. At baseline 24% of the patients 
reported waking up more than three times a night. Therefore, 
combined with the diary-recorded rating of the quality of 
sleep that indicated that there were no rebound effects, 
the difficulties with mid-sleep awakening after withdrawal 
probably indicate insomnia relapse in these patients.
In addition, there was no evidence of new somatic 
symptoms (whether possibly, probably, or definitely related 
to study treatment) that were not related to sleep   during 
withdrawal that had not been previously experienced at 
baseline.
During the withdrawal period following 6 months of 
open-label treatment, 24 patients (24%) reported somatic 
symptoms thought to be possibly, probably, or definitely 
related to study treatment, compared with 21 patients (22%) 
following 12 months of open-label treatment. This indicates 
that the use of PRM 2 mg over an additional 6 months 
does not increase the incidence of somatic symptoms on 
withdrawal of the drug. The most commonly reported 
somatic symptoms on PRM withdrawal were related to 
sleep. This is not clinically remarkable given the therapeutic 
area under study.
PRM has a much lower score for somatic symptoms 
at withdrawal compared with other drugs used for sleep 
promotion. The CHESS-84 withdrawal scores obtained for 
the discontinuation of PRM following 6 months of con-
tinuous use (1.37) were much lower than that reported for 
discontinuation after 8 weeks of treatment with lorazepam 
(7.06).26 It should be noted that patients did not receive 
any study medication during the withdrawal period and 
were aware of the fact that they had stopped the treatment 
drug. Therefore, the symptoms recorded on the CHESS-84 
are not masked by placebo effects. These data are in line 
with previous observations from short- and long-term stud-
ies indicating that PRM is not associated with significant 
withdrawal phenomena or rebound insomnia even following 
prolonged periods of use.
The long-term administration of PRM did not cause 
suppression of endogenous melatonin production as   evident 
by the rhythm in 6SMT in the urine. The presence of such 
rhythm also confirms that the 6SMT was endogenous rather 
than a metabolite of the residual PRM discontinued 2 weeks 
before. The reported observations are confirmatory and com-
patible with earlier reports in the literature on the lack of the 
suppressing effect of exogenous melatonin on its endogenous 
production.30–32Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Traditional hypnotics (eg, benzodiazepines) have been 
associated with marked rebound insomnia and withdrawal 
symptoms leading to unwarranted intake of these drugs for 
long-term periods.33,34 PRM has been shown to facilitate 
benzodiazepine discontinuation.35 The lack of rebound and 
withdrawal symptoms upon discontinuation of PRM use 
  suggests that this drug will potentially contribute to lowering 
of the inappropriate long-term intake of insomnia drugs.
Conclusion
It may be concluded that PRM 2 mg maintained efficacy 
during long-term treatment. PRM 2 mg was well tolerated, 
and there were no obvious differences in safety parameters 
between patients who had been treated for 6 months and 
those treated for 12 months. In addition, there appears to be 
no major safety concerns during PRM administration and 
following withdrawal of study medication up to 1 year of 
continuous use.
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